Navigation Links
Sanvar(R) (Debio 8609) for Esophageal Variceal Bleeding
Date:11/4/2008

Debiopharm Submits Response to the FDA

LAUSANNE, Switzerland, November 4 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, announced today that Debiovision Inc., its Canadian affiliate, filed its Complete Response to the approvable letter received from the United States (U.S.) Food and Drug Administration (FDA) for Sanvar(R), or Debio 8609 (vapreotide acetate). The immediate release formulation of Sanvar(R), a somatostatin analogue, is used in the treatment of acute esophageal variceal bleeding (EVB).

"This is an important step towards completing the U.S. registration of our drug. Sanvar(R) has demonstrated therapeutic benefit in the control of acute variceal bleeding prior to endoscopic treatment, an indication for which, to this day, no product has been approved by the FDA," said Rolland-Yves Mauvernay, president and founder of Debiopharm Group.

"Last summer, we completed a confirmatory phase III study in the U.S. Our study took place in over 20 centers and enrolled 103 patients including 70 that qualified for the intention-to-treat (ITT) analysis. Debioclinic S.A., the Group's French affiliate, participated with the statistical analysis of our study. The results of this study were an important component of the Complete Response and were submitted to the FDA on September 30th," added Jacques Guertin, president and CEO of Debiovision Inc.

Debiopharm has already signed license agreements for the sales and marketing of Sanvar(R), with several commercial partners that include Salix Pharmaceuticals in the U.S., Ranbaxy Laboratories Ltd in India, EMS Sigma Farma in Brasil, LG Life Sciences in Korea, Tzamal Bio-Pharma Ltd in Israel, and Medical Futures in Canada.

About Sanvar(R)

Sanvar(R) is used prior to endoscopic intervention to control haemorrhage and prevent re-bleeding during the critica
'/>"/>

SOURCE The Debiopharm Group
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Early Esophageal Cancer and Pre-Cancer Eliminated With Non-Surgical Treatment Combination
2. Its Only Heartburn...or is it? Chronic Heartburn a Risk Factor for Precursor to Esophageal Cancer
3. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
4. DG041 Blocks Platelet Aggregation Through a Novel Mechanism and does not Increase Bleeding Time When Given Alone or with Plavix(TM) or Aspirin
5. Ceremeds OSTENE(R) Stops Bone Bleeding Without Added Risk of Surgical Infection, New Study Finds
6. Cogentus to Launch Phase III Program of Novel Combination Product Designed to Reduce Bleeding Side Effect of Antiplatelet Therapy
7. Study Finds Starion Instruments Tissue Welding Technology Reduces Pain and Bleeding in Tonsillectomy Patients
8. Surgeons Develop Innovative Life-Saving Treatments to Correct Massive Bleeding in Trauma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... , July 7, 2015  Essentialis, a venture-backed company ... for the treatment of orphan neurobehavioral and metabolic diseases, today ... CSO, will present a corporate update at the Cantor Fitzgerald ... Date: Wednesday, July 8, 2015 Time: 8:00 ... About Essentialis, Inc. Essentialis ...
(Date:7/7/2015)... , July 7, 2015 Oramed ... a clinical-stage pharmaceutical company focused on the development of ... signed a non-binding Letter of Intent (LoI) for an ... with Sinopharm Capital Management Co. Ltd. and Hefei ... Ltd. (Sinopharm/ Hefei ) potentially valued at ...
(Date:7/6/2015)... July 6, 2015  Student-athletes at community colleges ... from a recently established partnership between ImPACT Applications, ... . The partnership enables member institutions of ... ImPACT ® concussion baseline and post-injury testing ... of community colleges in California ...
Breaking Medicine Technology:Sinopharm Capital-Hefei Signs Letter of Intent with Oramed for $50,000,000 Investment and Licensing Deal in China 2Sinopharm Capital-Hefei Signs Letter of Intent with Oramed for $50,000,000 Investment and Licensing Deal in China 3Sinopharm Capital-Hefei Signs Letter of Intent with Oramed for $50,000,000 Investment and Licensing Deal in China 4Sinopharm Capital-Hefei Signs Letter of Intent with Oramed for $50,000,000 Investment and Licensing Deal in China 5California Community College Athletic Departments to Benefit from ImPACT Concussion Baseline Testing Offered by Student Insurance 2California Community College Athletic Departments to Benefit from ImPACT Concussion Baseline Testing Offered by Student Insurance 3
(Date:7/7/2015)... ... ... Point is holding an onsite job fair to hire 400 people for its new site ... upcoming Wednesday, July 8, and Thursday, July 9, from 9:00 a.m. – 5:00 p.m. , ... well as holding onsite interviews. Interested parties are encouraged to attend the job fair ...
(Date:7/7/2015)... ... July 07, 2015 , ... Each year the Holiday Inn ... on a local, national and international level; however, the Holiday Inn now hosts one ... a high impact on the beneficiaries. In September of 2014 they hosted an event ...
(Date:7/6/2015)... Yorba Linda, CA (PRWEB) , ... July 06, ... ... human biology into the pre-clinical stages of drug discovery. iPSCs are generated from ... potential to differentiate into any cell type in the human body. , ...
(Date:7/6/2015)... ... ... “ TapGlance ” was featured on NewsWatch as part of its monthly AppWatch, ... iOS, Android, and Windows. Joe Toohey, the host of AppWatch and technology expert, conducted ... visualize what rooms will look like before they even start renovating.. , Whether a ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... On June 22, 2015, Fox News in a report titled “ Female ... time they turn age 35 a quarter of all women in the U.S. will suffer from ... is stigmatized and rarely discussed. One woman, a former beauty queen, who was interviewed ...
Breaking Medicine News(10 mins):Health News:Connexion Point, a tech enabled healthcare services company, is holding on-site job fair July 8th and 9th to fill 400 positions at its new Memphis location 2Health News:The Holiday Inn Westbury - Long Island Will Host a Fundraising Event on September 16th 2015 from 6:00 pm - 10:00 pm to Benefit Angela's House located on Long Island 2Health News:The Holiday Inn Westbury - Long Island Will Host a Fundraising Event on September 16th 2015 from 6:00 pm - 10:00 pm to Benefit Angela's House located on Long Island 3Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 2Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 3Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 4Health News:Create a Space with TapGlance, a Revolutionary Interior Design Application 2Health News:The Stigma of Female Hair Loss and Hair Restoration Solutions 2
... geographical areas in Southeast England according to a new study ... Health . The study shows that the occurrence of cervical ... Currin and her colleagues at the Thames Cancer Registry of ... cancer diagnosed between 2001 and 2005 in London, Kent, Surrey ...
... and programming in Canadian long-term care facilities fall short ... , Led by professor of Community Health and Epidemiology ... is the first comprehensive examination of these resources and ... that vulnerable long-term care residents be protected from largely ...
... 19 Esphera3 International (E3I) is a broad ... of "Patient Focused Care." Currently engaged in multiple ... of a partnered care health approach including operational ... financial operations of healthcare.E3I and its channel partners ...
... SHELBY TOWNSHIP, Mich., Feb. 19 Dr. Brett Kotlus ... Allure Medical Blog to share information,about new ... their practice. "I find that patients at our ... to sort through the tremendous,amount of information available on ...
... save lives and reduce disability, but less than 3% of ... (HealthDay News) -- A powerful clot-busting drug approved by the ... in 1996 is still rarely used in Medicare patients, new ... 495,000 admissions for stroke at the 4,750 hospitals evaluated were ...
... Insulet Corporation, (Nasdaq: PODD ), the leader ... Management System, announced plans to release its financial results ... Thursday, March 5, 2009 after the close of the ... 5:00 p.m. Eastern Time on Thursday, March 5, 2009 ...
Cached Medicine News:Health News:Infection prevention falls short in Canadian long-term care facilities 2Health News:Esphera3 International Founded on 'Patient Focused Care' 2Health News:Your Doctor Has a Blog 2Health News:Your Doctor Has a Blog 3Health News:Few Stroke Patients Get Clot-Busting Drug 2Health News:Few Stroke Patients Get Clot-Busting Drug 3
Threaded cannula with cannulated obturator for use with Acufex Suture Punch; sterile packs, box of 10....
Threaded cannula for use with Suretac® II, sterile packs, box of 10....
...
...
Medicine Products: